Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Prevention of Acute Mountain Sickness
NCT07653516Phase 4Not yet recruiting
- Sponsor
- Insel Gruppe
- Start
- Jun 2027
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 4 trial of fremanezumab in acute mountain sickness (AMS), sponsored by Insel Gruppe. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
fremanezumab
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT07653516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653516.